Stock Events

Stock Events

Vincerx Pharma 

$0.012700
42
-$0.00-2.31% Wednesday 17:57

Statistics

Day High
0.0053
Day Low
0.0053
52W High
0.07
52W Low
0.001
Volume
22
Avg. Volume
3,879
Mkt Cap
66,471.8
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

7NovExpected
Q1 2024
Q2 2024
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
-4.33
-2.91
-1.48
-0.05
Expected EPS
-2.4
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-30.07MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow VINC. It's not an investment recommendation.
NVIDIA
5
NVDA
Intel
5
INTC
SoFi Technologies
5
SOFI
Apple
4
AAPL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap181.18B
Gilead Sciences is a biopharmaceutical company that competes in the development of oncology and antiviral drugs, similar to Vincerx Pharma's focus on cancer and viral infections.
Bristol-Myers Squibb
BMY
Mkt Cap136.88B
Bristol Myers Squibb is involved in the discovery, development, and delivery of medicines related to cancer, competing directly with Vincerx Pharma's oncology segment.
Merck
MRK
Mkt Cap376.37B
Merck & Co. focuses on cancer drugs and vaccines, directly competing with Vincerx Pharma's research and development in oncology treatments.
Pfizer
PFE
Mkt Cap159.99B
Pfizer is a global biopharmaceutical company with a broad range of drugs including cancer treatments, making it a competitor to Vincerx Pharma.
Abbvie
ABBV
Mkt Cap468.22B
AbbVie operates in the discovery and sale of pharmaceuticals including oncology, directly competing with Vincerx Pharma's cancer-focused therapies.
AMGEN
AMGN
Mkt Cap237.52B
Amgen focuses on human therapeutics, including oncology and hematology, which competes with Vincerx Pharma's cancer treatment research.
Regeneron Pharmaceuticals
REGN
Mkt Cap85.87B
Regeneron Pharmaceuticals specializes in medicines for serious conditions including oncology, making it a competitor to Vincerx Pharma.
Novartis
NVS
Mkt Cap301.95B
Novartis is a global healthcare company that offers treatments in various areas including oncology, competing with Vincerx Pharma's focus areas.
Astrazeneca
AZN
Mkt Cap257.42B
AstraZeneca operates in several segments including oncology, directly competing with Vincerx Pharma's cancer treatment solutions.
Johnson & Johnson
JNJ
Mkt Cap651.25B
Johnson & Johnson, through its pharmaceutical segment Janssen, develops treatments for various diseases including cancer, competing with Vincerx Pharma.

About

Vincerx Pharma, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering and advancing innovative treatments for cancer, specifically addressing areas of high medical need within the U.S. Its primary therapeutic asset is VIP152, an inhibitor targeting cyclin-dependent kinase-9 (CDK9), designed for individuals battling advanced forms of cancer. Beyond this lead candidate, the company's pipeline features several preclinical-stage projects: VIP217, an orally administered PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate aimed at solid tumor treatment; and VIP943 and VIP924, both geared towards treating blood cancers. Established in 2019, Vincerx Pharma is based in Palo Alto, California.
Show more...
CEO
Raquel E. Izumi
Employees
13
Country
United States
ISIN
US92731L3042

Listings

OTC Link
US
VINC

0 Comments

Share your thoughts

FAQ

What is Vincerx Pharma stock price today?▼
The current price of VINC is $0.01 USD — it has decreased by -2.31% in the past 24 hours. Watch Vincerx Pharma stock price performance more closely on the chart.
What is Vincerx Pharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Vincerx Pharma stocks are traded under the ticker VINC.
Is Vincerx Pharma stock price growing?▼
VINC stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Vincerx Pharma has showed a -69.77% decrease.
What is Vincerx Pharma market cap?▼
Today Vincerx Pharma has the market capitalization of 66,471.8
What is Vincerx Pharma revenue for the last year?▼
Vincerx Pharma revenue for the last year amounts to 0 USD.
What is Vincerx Pharma net income for the last year?▼
VINC net income for the last year is -30.07M USD.
How many employees does Vincerx Pharma have?▼
As of August 28, 2026, the company has 13 employees.
In which sector is Vincerx Pharma located?▼
Vincerx Pharma operates in the Health & Wellness sector.
When did Vincerx Pharma complete a stock split?▼
The last stock split for Vincerx Pharma was on January 28, 2025 with a ratio of 1:20.
Where is Vincerx Pharma headquartered?▼
Vincerx Pharma is headquartered in Palo Alto, United States.